HomeQuestion

Do you make dose modifications to KEYNOTE-522 regimen in the elderly?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?

Are you routinely recommending adjuvant ribociclib now for node-negative HR+/HER2- breast cancer given data from the NATALEE trial?

What are your top takeaways in Breast Cancer from ESMO 2025?

How would you treat a patient with end-stage renal disease, a germline BRCA1 mutation, and pT1c pN0 TNBC s/p mastectomy?

How should poorly differentiated breast neuroendocrine carcinoma be treated in the neoadjuvant or adjuvant setting? Should chemotherapy follow small cell lung cancer regimens or standard breast cancer regimens, and do histologic subtype or biomarkers influence the choice?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.

Do you make dose modifications to KEYNOTE-522 regimen in the elderly? | Mednet